GlaxoSmithKline delivers 19% revenue growth for Q1 FY22
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This move positions the U.S.-based consumer healthcare company for a significantly larger role in the rapidly expanding at-home and retail diagnostic testing market
Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Conjugated Estrogens Tablets are indicated for moderate to severe menopausal symptoms, including hot flashes, and for the prevention of postmenopausal osteoporosis in women at significant risk
Subscribe To Our Newsletter & Stay Updated